Compare Gilead Sciences, Inc. (GILD) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs VNET Group Inc — how do they compare? Gilead Sciences, Inc. trades at $134.63 (market cap $163.51B), while VNET Group Inc trades at $7.77 (market cap $2.25B). The key difference: Gilead Sciences, Inc. is far larger — about 72.7× VNET Group Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while VNET Group Inc pays none. Which is the better fit depends on your goals.
| GILD | VNET | |
|---|---|---|
Market Cap | $163.51B | $2.25B |
Sector | Health | Technology |
52-Week High | $155.80 | $14.03 |
52-Week Low | $108.22 | $7.34 |
Enterprise Value | $178.05B | $5.38B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
VNET Group trades at $7.86, up 1.42% with bearish technical signals but strong analyst support. The company reported Q1 2026 revenue growth driven by AI demand, though net losses widened to -$1.20 per share. Recent strategic investments and leadership changes signal transformation, while a class action settlement adds legal overhang. The stock shows mixed fundamentals with negative profitability metrics but positive cash flow from operations.
VNET presents a high-risk opportunity with Wall Street optimism (62.5% buy ratings) pointing to 54% upside potential. Key risks include persistent losses, competitive pressures, and China market exposure. The AI-driven data center expansion offers growth potential, but investors need confidence in the path to profitability amid ongoing operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
